<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Ann Gastroenterol</journal-id>
<journal-id journal-id-type="iso-abbrev">Ann Gastroenterol</journal-id>
<journal-title-group>
<journal-title>Annals of Gastroenterology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1108-7471</issn>
<issn pub-type="epub">1792-7463</issn>
<publisher>
<publisher-name>Hellenic Society of Gastroenterology</publisher-name>
<publisher-loc>Greece</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29333064</article-id>
<article-id pub-id-type="pmc">5759610</article-id>
<article-id pub-id-type="publisher-id">AnnGastroenterol-31-24</article-id>
<article-id pub-id-type="doi">10.20524/aog.2017.0218</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Colorectal polyposis and inherited colorectal cancer syndromes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Byrne</surname>
<given-names>Raphael M.</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tsikitis</surname>
<given-names>Vassiliki Liana</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
<xref ref-type="corresp" rid="cor1"></xref>
</contrib>
</contrib-group>
<aff id="aff1">Department of Surgery, Division of GI and General Surgery, Oregon Health &amp; Science University, Portland, OR, USA</aff>
<author-notes>
<corresp id="cor1">
Correspondence to: Vassiliki Liana Tsikitis, MD, MCR, FACS, FASCRS, 3181 SW Sam Jackson Park Road, Mailcode L223A, Portland, OR 97239, USA, e-mail: <email xlink:href="tsikitis@ohsu.edu">tsikitis@ohsu.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<season>Jan-Feb</season>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>11</month>
<year>2017</year>
</pub-date>
<volume>31</volume>
<issue>1</issue>
<fpage>24</fpage>
<lpage>34</lpage>
<history>
<date date-type="received">
<day>31</day>
<month>8</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>10</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © Hellenic Society of Gastroenterology</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>The majority of colorectal cancer (CRC) cases are sporadic, with hereditary factors contributing to approximately 35% of CRC cases. Less than 5% of CRC is associated with a known genetic syndrome. Although adenomatous polyposis syndromes, hamartomatous polyposis syndromes, and those previously classified as non-polyposis CRC syndromes are quite rare, it is important for clinicians to know the characteristics of each syndrome and to understand the differences in cancer risks between the different conditions. This information is very important when treatment and surveillance plans are formulated for each individual patient.</p>
</abstract>
<kwd-group>
<kwd>Adenomatous polyposis syndromes</kwd>
<kwd>hamartomatous polyposis syndromes</kwd>
<kwd>nonpolyposis colorectal cancer syndromes</kwd>
<kwd>colorectal cancer</kwd>
<kwd>cancer risk</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1" sec-type="intro">
<title>Introduction</title>
<p>Most colorectal cancer (CRC) cases are sporadic, with hereditary factors contributing to approximately 35% of CRC cases [<xref ref-type="bibr" rid="ref1">1</xref>]. Less than 5% of CRC is associated with a known genetic syndrome [<xref ref-type="bibr" rid="ref2">2</xref>]. This review provides an overview of the most common colorectal polyposis syndromes and inherited CRC syndromes, including adenomatous polyposis, hamartomatous polyposis, serrated polyposis, and those previously classified as non-polyposis CRC syndromes. The surveillance recommendations reported for each syndrome are applicable for probands with positive genetic testing or for those with high clinical suspicion for the syndrome who have refused genetic testing. Probands with negative genetic testing should be screened according to established guidelines for those with first-degree relatives with CRC.</p>
<p>Screening and surveillance recommendations are summarized in <xref ref-type="table" rid="T3">Table 3</xref> at the end of the chapter.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Spigelman scoring system for duodenal adenomas</p>
</caption>
<graphic xlink:href="AnnGastroenterol-31-24-g001"></graphic>
</table-wrap>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>Recommendations based on Spigelman stage</p>
</caption>
<graphic xlink:href="AnnGastroenterol-31-24-g002"></graphic>
</table-wrap>
<table-wrap id="T3" position="float">
<label>Table 3</label>
<caption>
<p>Surveillance recommendations</p>
</caption>
<graphic xlink:href="AnnGastroenterol-31-24-g003"></graphic>
</table-wrap>
</sec>
<sec id="sec1-2">
<title>Familial adenomatous polyposis (FAP)</title>
<sec id="sec2-1">
<title>Epidemiology</title>
<p>In northern European populations, FAP has an incidence between 1/13,000 and 1/18,000 live births [<xref ref-type="bibr" rid="ref3">3</xref>]. It is the most common adenomatous polyposis syndrome, but is responsible for less than 1% of all CRC cases [<xref ref-type="bibr" rid="ref4">4</xref>]. The likelihood of having cancer at the time of diagnosis of FAP increases with age, with one Swedish study showing a median age of diagnosis of 42 for patients with FAP who were found to have CRC at the time of diagnosis, 34 for patients with FAP but without CRC at diagnosis, and 22 for asymptomatic relatives of other FAP patients [<xref ref-type="bibr" rid="ref5">5</xref>]. By the time patients with FAP are 40-50 years old, the risk of CRC approaches 100% [<xref ref-type="bibr" rid="ref6">6</xref>].</p>
</sec>
<sec id="sec2-2">
<title>Genetics</title>
<p>FAP is caused by a mutation in the <italic>APC</italic> gene, found on chromosome 5q21 [<xref ref-type="bibr" rid="ref7">7</xref>]. The mutation is inherited in an autosomal dominant fashion. The <italic>APC</italic> gene codes for a large tumor suppressor protein that affects cell adhesion and migration by regulating beta catenin as part of the Wnt-signaling pathway [<xref ref-type="bibr" rid="ref3">3</xref>]. Most cases of sporadic CRC involve mutations in the <italic>APC</italic> gene as part of the adenoma–carcinoma sequence [<xref ref-type="bibr" rid="ref7">7</xref>]. Many types and locations of <italic>APC</italic> mutations on the gene have been described in FAP. A genotype–phenotype correlation does exist, with mutations between codons 1250 and 1464 on the <italic>APC</italic> gene being associated with a severe form of FAP, and mutations at codon 1309 causing an especially severe form of the disease [<xref ref-type="bibr" rid="ref4">4</xref>].</p>
<p>With standard genetic testing, 20-30% of patients with clinical FAP have no identifiable mutation in the <italic>APC</italic> gene [<xref ref-type="bibr" rid="ref3">3</xref>]. One cross-sectional study demonstrated that the likelihood of identifying an <italic>APC</italic> mutation increased with the severity of the polyposis. In that study, an <italic>APC</italic> mutation was identified in 80% of patients with &gt;1000 adenomas, 56% with 100-999 adenomas, 10% with 20-99 adenomas, and 5% with 10-19 adenomas [<xref ref-type="bibr" rid="ref8">8</xref>]. With the development of more advanced genetic testing, such as monoallelic mutation analysis, <italic>APC</italic> mutation detection has greatly increased, with mutations identified in more than 95% of patients with clinical FAP [<xref ref-type="bibr" rid="ref3">3</xref>].</p>
</sec>
<sec id="sec2-3">
<title>Presentation and diagnosis</title>
<p>The diagnosis of FAP is based on the presence of 100 or more colorectal adenomas, or between 10 and 100 adenomas and a positive family history [<xref ref-type="bibr" rid="ref7">7</xref>]. Between 30-40% of cases occur in the absence of a positive family history [<xref ref-type="bibr" rid="ref4">4</xref>]. Adenomas most often develop in adolescence and are most commonly left-sided [<xref ref-type="bibr" rid="ref3">3</xref>]. The most common presenting symptoms are gastrointestinal (GI) bleeding, diarrhea, abdominal pain, and mucoid discharge [<xref ref-type="bibr" rid="ref7">7</xref>]. Approximately one quarter of patients will have CRC at the time of diagnosis [<xref ref-type="bibr" rid="ref7">7</xref>].</p>
<p>FAP is also associated with multiple extracolonic manifestations. These include upper GI adenomas (present in 95% of cases), gastric fundic gland polyps (80-90%), osteomas (80%), congenital hypertrophy of retinal pigment epithelium (CHRPE) (75%), epidermoid cysts (50%), dental anomalies (17%), desmoids (15-30%), and adrenocortical adenomas (5%). There are also associations with biliary tract cancers, papillary thyroid cancer, hepatoblastoma and medulloblastoma [<xref ref-type="bibr" rid="ref7">7</xref>]. CHRPE is characterized by a patchy discoloration of the fundus of the eye [<xref ref-type="bibr" rid="ref7">7</xref>].</p>
<p>Upper GI adenomas can be found in the stomach and throughout the small bowel, but occur most commonly in the duodenum, with 95% of patients having duodenal adenomas. Gastric adenomas are less common, occurring in 10% of patients. Gastric fundic gland polyps are very common and usually benign, although rarely can they progress to cancer. Given the very high prevalence of duodenal adenomas, it is not surprising that duodenal cancer is the second most common cause of death in FAP, after CRC [<xref ref-type="bibr" rid="ref7">7</xref>]. Duodenal adenomas form later in life than colorectal adenomas, and the average age of an FAP patient at the time of duodenal cancer diagnosis is 50 years. They are most commonly peri-ampullary and develop around 15 years after colorectal adenomas. The duodenal adenoma burden is scored using the Spigelman staging system, which takes into account adenoma size, number, histology, and dysplasia (<xref ref-type="table" rid="T1">Table 1</xref>) [<xref ref-type="bibr" rid="ref9">9</xref>]. The Spigelman score is used to determine the appropriate interval between upper endoscopies, which ranges from six months to five years (<xref ref-type="table" rid="T2">Table 2</xref>) [<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref>].</p>
<p>Desmoids are locally invasive tumors of mesenchymal origin, arising from myofibroblasts [<xref ref-type="bibr" rid="ref11">11</xref>]. They most often occur in the absence of an underlying syndrome, but patients with FAP have an incidence of desmoids that is 850 times that of the general population [<xref ref-type="bibr" rid="ref11">11</xref>]. They are most commonly found intra-abdominally and in the abdominal wall, representing the third most common cause of death in FAP, usually from bowel obstruction [<xref ref-type="bibr" rid="ref7">7</xref>]. Known risk factors for the development of desmoids in FAP are female sex, prior surgery, and family history of desmoids [<xref ref-type="bibr" rid="ref11">11</xref>].</p>
</sec>
<sec id="sec2-4">
<title>Cancer risk and surveillance</title>
<p>CRC risk is essentially 100% by the time patients reach age 40-50 [<xref ref-type="bibr" rid="ref3">3</xref>]. FAP patients are also at increased risk of duodenal, gastric, thyroid, and biliary tract cancers. Endoscopic screening of FAP patients and their family members has reduced the rate of CRC at the time of FAP diagnosis by 55% [<xref ref-type="bibr" rid="ref3">3</xref>]. Screening has also increased their overall survival [<xref ref-type="bibr" rid="ref3">3</xref>]. Screening recommendations differ slightly between American and European societies. The American Gastroenterological Association (AGA) recommends annual sigmoidoscopy for probands and their relatives, starting between ages 10-12 [<xref ref-type="bibr" rid="ref3">3</xref>]. The European Society of Medical Oncologists (ESMO) recommends sigmoidoscopy every two years, starting between ages 12-14 [<xref ref-type="bibr" rid="ref4">4</xref>]. Once adenomas are identified, annual colonoscopy is performed until prophylactic colectomy. Upper endoscopy with both front- and side-viewing scopes is also an essential part of screening and surveillance [<xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref4">4</xref>]. Upper endoscopy should begin once colorectal polyps are identified, or between ages 25-30, whichever comes first [<xref ref-type="bibr" rid="ref4">4</xref>]. Once duodenal adenomas are identified, surveillance frequency and treatment are guided by the Spigelman staging system [<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref>]. ESMO also recommends annual cervical ultrasound for thyroid cancer screening [<xref ref-type="bibr" rid="ref4">4</xref>].</p>
</sec>
<sec id="sec2-5">
<title>Treatment</title>
<p>The three surgical options for patients with FAP are total abdominal colectomy (TAC) with ileorectal anastomosis, total proctocolectomy (TPC) with ileal pouch anal anastomosis (IPAA), and TPC with end ileostomy. The timing of surgery depends on the severity of polyposis, the presence of dysplasia or malignancy, the presence of symptoms, and the intellectual and physical maturity of the patient, with most patients undergoing surgery between ages 15-25 [<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref7">7</xref>]. Surgery should be performed as soon as possible in the presence of severe polyposis with &gt;1000 adenomas or &gt;20 rectal adenomas, in the symptomatic patient, and when high-grade dysplasia is present [<xref ref-type="bibr" rid="ref7">7</xref>].</p>
<p>Full colonoscopy with biopsies is mandatory prior to surgical intervention. TAC with ileorectal anastomosis can be offered to young patients without severe polyposis, with a low rectal polyp burden (fewer than 5-10 rectal polyps), and without high-grade dysplasia [<xref ref-type="bibr" rid="ref7">7</xref>]. There is a risk of developing cancer in the remaining rectum after TAC with ileorectal anastomosis. The cumulative risk of rectal cancer in patients with FAP after TAC with ileorectal anastomosis is estimated at 10% at 50 years of age and 29% at 60 years [<xref ref-type="bibr" rid="ref3">3</xref>]. Although the risk of eventually developing rectal cancer is relatively high, one study showed that the mortality rate from rectal cancer after TAC and ileorectal anastomosis was only 2% after 15-year follow up [<xref ref-type="bibr" rid="ref12">12</xref>]. Because of the high rates of rectal polyp and rectal cancer development, postoperative surveillance endoscopy should be performed every six months to one year [<xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref7">7</xref>]. When rectal polyps are encountered, they should be removed endoscopically, if feasible. If rectal polyposis develops that is not endoscopically controllable, or if high-grade dysplasia is present, a completion proctectomy should be performed with either IPAA or end ileostomy [<xref ref-type="bibr" rid="ref7">7</xref>].</p>
<p>Total proctocolectomy with IPAA involves removing the rectum and colon, and is thus preferred in cases of severe polyposis, for patients with significant rectal polyposis, and in the presence of high-grade dysplasia [<xref ref-type="bibr" rid="ref7">7</xref>]. Previous teachings have advised proceeding straight to TPC rather than TAC in patients with a strong family history of desmoid disease, for fear it would make future completion proctectomy very difficult, if not impossible, to perform if eventually required. Recent data from a tertiary care center, however, has demonstrated that desmoid disease does not prevent the performance of completion proctectomy [<xref ref-type="bibr" rid="ref13">13</xref>]. Studies have shown a lower incidence of duodenal adenomas after IPAA than after ileorectal anastomosis, possibly because alterations in the enterohepatic circulation cause decreased bile acid production. TPC with IPAA may therefore be the preferred initial surgical option for patients with a family history of significant duodenal polyposis [<xref ref-type="bibr" rid="ref7">7</xref>]. TPC with IPAA is associated with a significant decrease in female fertility, compared with TAC and ileorectal anastomosis [<xref ref-type="bibr" rid="ref3">3</xref>]. This should be discussed with women of child-bearing age prior to surgery, with one option being to proceed with TAC and ileorectal anastomosis initially, with plans to perform completion proctectomy and IPAA once child bearing is complete.</p>
<p>When performing TPC with IPAA, there is debate as to whether a stapled anastomosis or a mucosectomy and hand-sewn anastomosis is the best approach. The former requires leaving a 1-2 cm cuff of mucosa in the distal rectum and anal transition zone, while the latter removes as much mucosa as possible. Stapled IPAA anastomosis provides for significantly better functional outcomes, with less incontinence, seepage, and pad usage, but it also leads to a higher rate of polyps in the anal transition zone on postoperative endoscopic surveillance [<xref ref-type="bibr" rid="ref14">14</xref>]. With either method, the risk of ileal pouch polyps is quite high after TPC with IPAA. The risk of ileal polyps is 7% at 5 years after surgery, 35% at 10 years, and 75% at 15 years [<xref ref-type="bibr" rid="ref3">3</xref>]. Annual surveillance pouch endoscopy is recommended. TPC with IPAA is not a good option for patients with poor preexisting sphincter function, nor for those with advanced rectal cancer, and TPC with end ileostomy should be performed instead.</p>
<p>Treatment of desmoid disease is difficult, because of the very high rates of recurrence after surgery (up to 50%) and their tendency to involve the root of the mesentery [<xref ref-type="bibr" rid="ref7">7</xref>]. Surgery is often avoided in the case of intra-abdominal desmoids, unless the patient is symptomatic, usually from bowel obstruction or ischemia. Duodenal polyposis is often treated with frequent endoscopic surveillance and polypectomies, according to the Spigelman staging system. In the most severe cases (Spigelman stage IV), duodenectomy is indicated. This can be achieved with a pancreas-preserving total duodenectomy, which has been shown to have similar short-term morbidity and mortality to a Whipple procedure [<xref ref-type="bibr" rid="ref15">15</xref>]. In the case of duodenal carcinoma, a Whipple procedure is indicated.</p>
<p>Although surgery is the mainstay of treatment for FAP, some medical treatments have been used for prevention of adenoma formation. Both sulindac, a non-steroid anti-inflammatory, and celecoxib, a cyclo-oxygenase-2 inhibitor, have been shown to reduce the number and size of rectal polyps by inducing apoptosis, with a decrease in number as high as 72% [<xref ref-type="bibr" rid="ref4">4</xref>]. Despite the significant decrease in size and number of polyps, no reduction in cancer risk has been shown [<xref ref-type="bibr" rid="ref7">7</xref>].</p>
</sec>
</sec>
<sec id="sec1-3">
<title>Attenuated FAP</title>
<p>Attenuated FAP is characterized by fewer adenomas that develop later in life than do those in patients with FAP. It is defined as the presence of fewer than 100 adenomas. Adenomas usually develop in the fourth and fifth decades of life, with CRC developing in the sixth and seventh decades of life [<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref7">7</xref>]. Like FAP, it is characterized by a germline mutation in the <italic>APC</italic> gene. Patients with attenuated FAP can have extracolonic manifestations, such as duodenal adenomas and fundic gland polyps, but do not have CHRPE [<xref ref-type="bibr" rid="ref7">7</xref>]. Full colonoscopy is the appropriate screening tool, because adenomas can be localized to the right colon. ESMO guidelines recommend a colonoscopy every two years, starting between ages 18-20. Once adenomas are identified, colonoscopy should be performed annually [<xref ref-type="bibr" rid="ref4">4</xref>]. Treatment for attenuated FAP is endoscopic polypectomy and annual colonoscopy if the polyp burden remains controllable endoscopically. If it does not, then TAC is warranted, with the same postoperative surveillance as in FAP [<xref ref-type="bibr" rid="ref7">7</xref>].</p>
</sec>
<sec id="sec1-4">
<title>MutY homolog-associated polyposis (MAP)</title>
<sec id="sec2-6">
<title>Epidemiology</title>
<p>MAP is a rare autosomal recessive adenomatous polyposis syndrome. Heterozygous carriers of the two most common mutations associated with MAP make up 1-2% of the population in North America and Europe [<xref ref-type="bibr" rid="ref2">2</xref>]. The median age of diagnosis is 48 [<xref ref-type="bibr" rid="ref16">16</xref>].</p>
</sec>
<sec id="sec2-7">
<title>Genetics</title>
<p>MAP is caused by biallelic mutations in the <italic>MYH</italic> gene. The inheritance pattern is autosomal recessive with high penetrance [<xref ref-type="bibr" rid="ref4">4</xref>]. The <italic>MYH</italic> gene codes for a protein that repairs oxidative DNA damage. It does this by excising adenine base pairs that are misincorporated instead of cytosine [<xref ref-type="bibr" rid="ref16">16</xref>]. Two missense mutations, Y179C and G396D, are by far the most common, and are present in up to 70% of patients with MAP [<xref ref-type="bibr" rid="ref17">17</xref>]. Y179C is associated with a more severe phenotype [<xref ref-type="bibr" rid="ref7">7</xref>]. Of all polyposis patients, biallelic <italic>MYH</italic> mutations were identified in 2% of patients with &gt;1000 adenomas, 7% of patients with 100-999 adenomas, 7% of patients with 20-99 adenomas, and 4% of those with 10-19 adenomas [<xref ref-type="bibr" rid="ref18">18</xref>].</p>
</sec>
<sec id="sec2-8">
<title>Presentation and diagnosis</title>
<p>Diagnosis is made with colonoscopy. Most patients have fewer than 100 adenomas, but some can have severe polyposis [<xref ref-type="bibr" rid="ref4">4</xref>]. Polyps tend to be right-sided in MAP [<xref ref-type="bibr" rid="ref7">7</xref>]. Patients are typically diagnosed in their 40s and 50s, and the average age at CRC diagnosis is 50 [<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref16">16</xref>]. Patients with MAP are at risk of extracolonic manifestations, including duodenal adenomas; the risk, however, is much lower than in FAP, with &lt;5% of MAP patients affected [<xref ref-type="bibr" rid="ref17">17</xref>].</p>
</sec>
<sec id="sec2-9">
<title>Cancer risk and surveillance</title>
<p>Biallelic <italic>MYH</italic> mutation carriers have an 80% risk of developing CRC by the time they are 70 years old [<xref ref-type="bibr" rid="ref7">7</xref>]. While cancer most often develops in the setting of polyposis, up to one third of biallelic carriers develop CRC without an associated polyposis [<xref ref-type="bibr" rid="ref4">4</xref>]. Monoallelic <italic>MYH</italic> mutation carriers also have an increased risk of developing CRC, with one study reporting a standardized incidence ratio of 2.12, comparable to that of a first-degree relative of a patient with sporadic CRC [<xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref19">19</xref>]. Although CRC risk is elevated in monoallelic carriers, CRC mortality, overall cancer risk, and overall mortality are not elevated in this group [<xref ref-type="bibr" rid="ref16">16</xref>].</p>
<p>ESMO recommendations for surveillance for biallelic <italic>MYH</italic> carriers are colonoscopy every two years, starting between ages 18-20, in addition to esophagogastroduodenoscopy (EGD) starting between ages 25-30 [<xref ref-type="bibr" rid="ref4">4</xref>]. Colonoscopy becomes annual once adenomas are found. For monoallelic <italic>MYH</italic> mutation carriers, a screening regimen identical to that of a first-degree relative of a patient with sporadic CRC is recommended [<xref ref-type="bibr" rid="ref4">4</xref>].</p>
</sec>
<sec id="sec2-10">
<title>Treatment</title>
<p>Treatment strategies for MAP are similar to those for attenuated FAP. Endoscopic surveillance and polypectomy can be performed for as long as the polyp burden remains endoscopically controllable; a colectomy, however, is eventually required for most patients [<xref ref-type="bibr" rid="ref4">4</xref>]. Annual surveillance endoscopy is recommended after surgery.</p>
</sec>
</sec>
<sec id="sec1-5">
<title>Peutz-Jeghers syndrome (PJS)</title>
<sec id="sec2-11">
<title>Epidemiology</title>
<p>PJS is a rare autosomal dominant syndrome associated with a hamartomatous polyposis throughout the GI tract. The syndrome confers an increased risk of a variety of cancers. Overall incidence of PJS is estimated at 1/200,000 [<xref ref-type="bibr" rid="ref7">7</xref>].</p>
</sec>
<sec id="sec2-12">
<title>Genetics</title>
<p>PJS is caused by a mutation with autosomal dominant inheritance on a gene on chromosome 19, known by two names, LKB1 and STK11. This gene is a tumor suppressor gene [<xref ref-type="bibr" rid="ref20">20</xref>]. Between 80% and 94% of families with PJS phenotype have an identifiable LKB1/STK11 mutation [<xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref22">22</xref>].</p>
</sec>
<sec id="sec2-13">
<title>Presentation and diagnosis</title>
<p>For patients without a family history of PJS, the World Health Organization (WHO) diagnostic criteria require three or more histologically-confirmed PJS polyps, or any number of histologically confirmed PJS polyps, and the characteristic mucocutaneous pigmentation. For patients with a family history of PJS, the WHO diagnostic criteria are any number of histologically confirmed PJS polyps, or the characteristic mucocutaneous pigmentation [<xref ref-type="bibr" rid="ref23">23</xref>]. PJS polyps are hamartomas and are histologically described as a central core of smooth muscle that shows tree-like branching, covered by native mucosa heaped into folds, creating a villous pattern [<xref ref-type="bibr" rid="ref24">24</xref>]. These polyps can develop anywhere throughout the GI tract, but are most common in the small bowel (78%), stomach (38%), colon (42%), and rectum (28%) [<xref ref-type="bibr" rid="ref7">7</xref>]. The characteristic mucocutaneous pigmentation is a prominent melanin pigmentation in the perioral, peribuccal, and/or the genital regions. This pigmentation occurs in childhood, and typically fades when the patient is in his or her late 20s [<xref ref-type="bibr" rid="ref7">7</xref>].</p>
<p>Presenting symptoms are most commonly related to anemia from chronic GI blood loss, as well as bowel obstruction [<xref ref-type="bibr" rid="ref7">7</xref>]. Large PJS polyps can also act as a lead point and lead to an intussusception as an acute presentation [<xref ref-type="bibr" rid="ref24">24</xref>].</p>
</sec>
<sec id="sec2-14">
<title>Cancer risk and surveillance</title>
<p>The lifetime risk of cancer of any type in PJS is estimated to be 90%. Patients with PJS develop an extensive variety of cancers, with 20% developing CRC, 30% breast, 30% pancreas, 5% gastric, and others developing ovarian sex-cord tumors, pulmonary cancers, and cervical cancers [<xref ref-type="bibr" rid="ref7">7</xref>]. A prospective study by van Lier <italic>et al</italic> spanning 14 years, has provided us with some robust data on cancer risk in PJS [<xref ref-type="bibr" rid="ref24">24</xref>]. The cumulative risk for all cancers was 20% at age 40 and 76% at age 70, with the risk for GI cancer being 12% and 51% at the respective ages. The median age at first cancer diagnosis was 45. Cancer risk is significantly higher in women with PJS than in men with PJS, with a hazard ratio of 20.40 in women and 4.76 in men. This sex-related difference likely represents the high predisposition to breast and gynecologic cancers in the PJS population [<xref ref-type="bibr" rid="ref24">24</xref>]. There was no difference between men and women in terms of GI cancer risk. Overall mortality was elevated in PJS patients compared to the general population, with a hazard ration of 3.50 and no statistically significant difference between sexes.</p>
<p>Surveillance recommendations for PJS are quite extensive, and reflect the wide variety of cancers that patients with PJS are predisposed to developing. Recommendations include yearly history and physical, capsule endoscopy every 2-3 years starting at age 10, EGD every 2-5 years starting at age 20, colonoscopy every 2-5 years starting between ages 25-30, magnetic resonance imaging (MRI) and/or endoscopic ultrasound of the pancreas every year starting at age 30, breast exam and breast MRI every year starting at age 25, mammography and breast MRI starting at age 30, pelvic exam, pap smear, transvaginal ultrasound, and CA-125 every year starting between ages 25-30 [<xref ref-type="bibr" rid="ref24">24</xref>].</p>
</sec>
<sec id="sec2-15">
<title>Treatment</title>
<p>Given the wide variety of cancers that patients with PJS may develop, surgical treatment is highly dependent on the type and location of the cancer. Colorectal polyps can usually be managed endoscopically, with polyps &gt;1.5 cm necessitating removal [<xref ref-type="bibr" rid="ref7">7</xref>].</p>
</sec>
</sec>
<sec id="sec1-6">
<title>Juvenile polyposis syndrome (JPS)</title>
<sec id="sec2-16">
<title>Epidemiology</title>
<p>Juvenile polyps are hamartomas that lack smooth muscle [<xref ref-type="bibr" rid="ref7">7</xref>]. They are the most common colorectal lesion in children. They are most commonly solitary and not associated with a syndrome or any malignant potential [<xref ref-type="bibr" rid="ref7">7</xref>]. When they are part of JPS, however, they are associated with malignant potential and other anomalies. The overall incidence is 1/100,000, and the average age at diagnosis is nine years [<xref ref-type="bibr" rid="ref7">7</xref>].</p>
</sec>
<sec id="sec2-17">
<title>Genetics</title>
<p>JPS has an autosomal dominant inheritance. Germline mutations in <italic>SMAD4</italic> and <italic>BMPR1A</italic> have been implicated, with a mutation in either one identified in 39% of patients with the clinical syndrome [<xref ref-type="bibr" rid="ref25">25</xref>]. Patients with <italic>SMAD4</italic> mutations are more likely to have gastric polyposis and hereditary hemorrhagic telangiectasias [<xref ref-type="bibr" rid="ref26">26</xref>].</p>
</sec>
<sec id="sec2-18">
<title>Presentation and diagnosis</title>
<p>The diagnostic criteria for JPS are five or more colorectal juvenile polyps in the absence of a positive family history, any number of juvenile polyps with a positive family history, or multiple juvenile polyps in the upper and lower GI tract [<xref ref-type="bibr" rid="ref7">7</xref>]. JPS always involves the colon, and the stomach and small bowel are each involved in 50% of cases [<xref ref-type="bibr" rid="ref7">7</xref>]. Polyps most often develop by the third decade of life [<xref ref-type="bibr" rid="ref27">27</xref>]. Between 10% and 20% of patients have associated congenital anomalies, such as macrocephaly, congenital heart disease, cleft lip and palate, genitourinary malformations, malrotation, telangiectasias, and GI and pulmonary arteriovenous malformations [<xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref26">26</xref>]. The most common presenting symptoms are rectal bleeding, anemia, and polyp prolapse [<xref ref-type="bibr" rid="ref7">7</xref>].</p>
</sec>
<sec id="sec2-19">
<title>Cancer risk and surveillance</title>
<p>The lifetime CRC risk for those with JPS is 39%, while that for gastric cancer is 21% [<xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref27">27</xref>]. Mean age at the time of diagnosis of CRC is 44, and there is no difference in risk between men and women [<xref ref-type="bibr" rid="ref27">27</xref>]. Recommended screening for first-degree relatives includes colonoscopy and EGD every 1-3 years, starting at age 12, then switching to annual surveillance once polyps are found [<xref ref-type="bibr" rid="ref28">28</xref>].</p>
</sec>
<sec id="sec2-20">
<title>Treatment</title>
<p>Endoscopic surveillance and polypectomy is reasonable if the polyp load is controllable endoscopically. If the polyposis becomes uncontrollable, colectomy is required [<xref ref-type="bibr" rid="ref7">7</xref>].</p>
</sec>
</sec>
<sec id="sec1-7">
<title>PTEN hamartoma tumor syndrome (PHTS)</title>
<sec id="sec2-21">
<title>Epidemiology</title>
<p>PHTS refers to multiple rare syndromes involving mutations in the <italic>PTEN</italic> gene, most notably Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome (BRRS). Cowden syndrome is more common in adults and women, while BRRS is most common in children and men [<xref ref-type="bibr" rid="ref29">29</xref>].</p>
</sec>
<sec id="sec2-22">
<title>Genetics</title>
<p>PHTS is characterized by germline mutations in the tumor suppressor gene, <italic>PTEN</italic>. This gene is located on chromosome 10q23 and plays an important role in inhibiting the mTOR and MAPK pathways [<xref ref-type="bibr" rid="ref30">30</xref>-<xref ref-type="bibr" rid="ref33">33</xref>]. PHTS is inherited in an autosomal dominant fashion and has 80% penetrance [<xref ref-type="bibr" rid="ref33">33</xref>].</p>
</sec>
<sec id="sec2-23">
<title>Presentation and diagnosis</title>
<p>PHTS has many associated anomalies, including macrocephaly, developmental delay, and autism. Macrocephaly is the most consistent, with 94% of patients having ahead circumference more than two standard deviations larger than normal [<xref ref-type="bibr" rid="ref34">34</xref>]. Characteristic oral mucosal papillomatosis, as well as penile freckling are also associated with PHTS [<xref ref-type="bibr" rid="ref29">29</xref>]. Most patients have thyroid disease, usually nodules or Hashimoto’s thyroiditis, especially with Cowden syndrome. Trichilemommas, benign papular skin tumors, are pathognomonic for Cowden syndrome [<xref ref-type="bibr" rid="ref7">7</xref>].</p>
</sec>
<sec id="sec2-24">
<title>Cancer risk and surveillance</title>
<p>Tan <italic>et al</italic> published the largest prospective study (368 patients) to examine cancer risks associated with PHTS [<xref ref-type="bibr" rid="ref33">33</xref>]. The cumulative lifetime risk of breast cancer was 85%, thyroid cancer was 35%, endometrial cancer was 28%, CRC was 9%, kidney cancer was 34%, and melanoma was 6% [<xref ref-type="bibr" rid="ref33">33</xref>]. The cancer with the earliest average age of onset is thyroid cancer [<xref ref-type="bibr" rid="ref29">29</xref>]. The vast majority (80-93%) of PHTS patients who undergo colonoscopy have polyps. The most common type of colorectal polyp is hyperplastic, followed by hamartoma [<xref ref-type="bibr" rid="ref29">29</xref>].</p>
<p>Screening recommendations from the National Comprehensive Cancer Network include annual mammography and breast MRI starting at age 30, annual thyroid ultrasound from the age of diagnosis, optional transvaginal ultrasound and endometrial sampling, renal imaging every 1-2 years starting at age 40, colonoscopy at least every five years starting between ages 35-40, and annual skin examination [<xref ref-type="bibr" rid="ref29">29</xref>]. Given that the breast cancer risk is similar to than in BRCA, prophylactic mastectomy is an option and should be discussed with the patient. Prophylactic hysterectomy is also an option, given the high risk of endometrial cancer [<xref ref-type="bibr" rid="ref29">29</xref>]. Prophylactic oophorectomy is not necessary, as ovarian cancer risk is not elevated.</p>
</sec>
</sec>
<sec id="sec1-8">
<title>Serrated polyposis syndrome (SPS)</title>
<sec id="sec2-25">
<title>Epidemiology</title>
<p>SPS was formerly known as hyperplastic polyposis syndrome. Diagnosis usually occurs in the sixth and seventh decades of life [<xref ref-type="bibr" rid="ref35">35</xref>-<xref ref-type="bibr" rid="ref37">37</xref>]. Men and women appear to be affected equally [<xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref37">37</xref>].</p>
</sec>
<sec id="sec2-26">
<title>Genetics</title>
<p>No specific germline mutation has been identified for SPS. The base excision repair genes <italic>MBD4</italic> and <italic>MYH</italic> have been investigated in SPS with no significant association [<xref ref-type="bibr" rid="ref38">38</xref>]. A family history of CRC is quite common in SPS, with large series reporting a positive family history in 38-50% of SPS patients [<xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref38">38</xref>]. The proposed mechanism of carcinogenesis in serrated polyps is hypermethylation causing inactivation of tumor suppressor genes. These tumors are commonly labeled CIMP (CpG island methylator phenotype) high [<xref ref-type="bibr" rid="ref37">37</xref>].</p>
</sec>
<sec id="sec2-27">
<title>Presentation and diagnosis</title>
<p>The diagnosis of SPS is defined by the WHO based on any one of the following criteria: 1) 20 or more serrated polyps anywhere in the colon; 2) 5 or more serrated polyps proximal to the sigmoid colon, with 2 polyps &gt;1 cm; or 3) at least 1 serrated polyp proximal to the sigmoid colon and a first-degree relative with SPS [<xref ref-type="bibr" rid="ref39">39</xref>]. Symptoms are uncommon, and diagnosis is usually made during screening colonoscopy [<xref ref-type="bibr" rid="ref26">26</xref>]. Sessile serrated polyps can be difficult to detect on colonoscopy as they are similar in color to the surrounding mucosa. Identification of the characteristic yellow or green mucus cap is helpful in identifying these lesions [<xref ref-type="bibr" rid="ref37">37</xref>].</p>
<p>Kalady <italic>et al</italic> have proposed at least three distinct clinical phenotypes within SPS. In their large series of 115 patients, they found 48% had relatively few large right-sided polyps, 16% had many small left-sided polyps, and 36% had a combination of left- and right-sided polyps. They found that the right-sided phenotype had an increased risk of CRC at a younger age [<xref ref-type="bibr" rid="ref35">35</xref>].</p>
</sec>
<sec id="sec2-28">
<title>Cancer risk and surveillance</title>
<p>A multicenter retrospective study of 77 patients with SPS found that 29% of patients had CRC at the time of their initial screening endoscopy. Five patients developed CRC during the study period, and the cumulative risk of CRC under surveillance was calculated to be 7% at five years [<xref ref-type="bibr" rid="ref36">36</xref>]. An increasing number of serrated polyps was significantly associated with the development of cancer [<xref ref-type="bibr" rid="ref36">36</xref>].</p>
<p>Once the diagnosis of SPS is made, annual colonoscopy should be performed. All serrated polyps should be removed if possible, or all polyps ≥5 mm should be removed if there are many diminutive polyps [<xref ref-type="bibr" rid="ref37">37</xref>]. Due to the large proportion of SPS patients with a positive family history of CRC, screening colonoscopy is recommended for all first-degree relatives of SPS patients starting at 40 years old or at 10 years younger than the age of diagnosis of SPS [<xref ref-type="bibr" rid="ref37">37</xref>]. Full colonoscopy should then continue at 5-year intervals if no polyps are found [<xref ref-type="bibr" rid="ref37">37</xref>].</p>
</sec>
<sec id="sec2-29">
<title>Treatment</title>
<p>Annual colonoscopy with polypectomy can be performed as long as the polyp burden remains endoscopically controllable. When CRC develops, or when it is no longer feasible to control the polyp burden endoscopically, surgery is indicated. Surgical treatment most commonly consists of segmental oncologic resection of the cancer as well as segments with large polyps [<xref ref-type="bibr" rid="ref37">37</xref>]. Annual endoscopic surveillance of the remaining rectum and colon is required postoperatively [<xref ref-type="bibr" rid="ref37">37</xref>].</p>
</sec>
</sec>
<sec id="sec1-9">
<title>Lynch syndrome</title>
<sec id="sec2-30">
<title>Epidemiology</title>
<p>Lynch syndrome involves autosomal dominant mutations in mismatch repair (MMR) genes. It carries an increased CRC risk without an associated polyposis. It is the most common hereditary cancer syndrome, accounting for 1-3% of all CRC cases [<xref ref-type="bibr" rid="ref4">4</xref>]. In addition to CRC, Lynch syndrome is also associated with a variety of other cancers.</p>
</sec>
<sec id="sec2-31">
<title>Genetics</title>
<p>Lynch syndrome is characterized by autosomal dominant mutations in four different MMR genes: <italic>MLH1</italic>, <italic>MSH2</italic>, <italic>MSH6</italic>, and <italic>PMS2</italic> [<xref ref-type="bibr" rid="ref4">4</xref>]. The incidences of the different mutations are quite different, with <italic>MLH1</italic> and <italic>MSH2</italic> mutations accounting for 80% of mutations, <italic>MSH6</italic> making up 10-12%, and <italic>PMS2</italic> accounting for 2-3% [<xref ref-type="bibr" rid="ref40">40</xref>]. There is an established genotype–phenotype correlation: <italic>MLH1</italic> mutations are associated with a higher risk of young-onset CRC, <italic>MSH2</italic> with a higher risk of extracolonic cancer, <italic>MSH6</italic> with an increased risk of endometrial cancer, while <italic>PMS2</italic> are associated with the lowest risk of CRC and endometrial cancer and later-onset cancers [<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref41">41</xref>].</p>
</sec>
<sec id="sec2-32">
<title>Presentation and diagnosis</title>
<p>The Amsterdam criteria and Bethesda criteria are two diagnostic tools used to identify patients at risk for Lynch syndrome.</p>
<sec id="sec3-1">
<title>Amsterdam II criteria</title>
<p>
<list list-type="simple"><list-item><p>1)Three or more relatives with a Lynch-associated cancer (CRC, endometrial, small bowel, genitourinary), with one being a first-degree relative of the other two</p></list-item><list-item><p>2)Two or more successive generations</p></list-item><list-item><p>3)One or more before the age of 50</p></list-item><list-item><p>4)Exclusion of FAP [<xref ref-type="bibr" rid="ref42">42</xref>]</p></list-item></list>
</p>
<p>The revised Bethesda criteria state that a tumor should be tested for microsatellite instability (MSI) in any of the following circumstances:</p>
<p>
<list list-type="simple"><list-item><p>1)CRC in a patient aged &lt;50</p></list-item><list-item><p>2)Synchronous or metachronous CRC or other Lynch-associated tumors</p></list-item><list-item><p>3)CRC with high-level MSI histology in a patient aged &lt;60</p></list-item><list-item><p>4)CRC in one or more first-degree relatives with a Lynch-related tumor, with one of the cancers diagnosed at less than 50 years old</p></list-item><list-item><p>5)CRC in two or more first- or second-degree relatives with Lynch-related tumors [<xref ref-type="bibr" rid="ref43">43</xref>].</p></list-item></list>
</p>
<p>While these two sets of criteria are helpful, their sensitivity in identifying patients with Lynch syndrome is low. The Bethesda guidelines have been shown to miss 6-25% of patients with Lynch syndrome [<xref ref-type="bibr" rid="ref44">44</xref>]. The gold standard for diagnostic testing is germline sequencing of the MMR genes. MMR sequencing of all CRCs in patients younger than age 70 should be performed, and universal testing for all CRCs, regardless of age, is the diagnostic approach that is most sensitive in identifying Lynch syndrome patients [<xref ref-type="bibr" rid="ref45">45</xref>].</p>
</sec>
</sec>
<sec id="sec2-33">
<title>Cancer risk and surveillance</title>
<p>Lynch syndrome carriers have a lifetime CRC risk of 15-70%; those with <italic>PMS2</italic> mutations have the lowest risk (15-20%) [<xref ref-type="bibr" rid="ref40">40</xref>,<xref ref-type="bibr" rid="ref41">41</xref>]. There is also a significant lifetime risk of other Lynch-associated cancers. These include endometrial (30-60% lifetime risk), genitourinary (8%), ovarian (4-12%), pancreatic (4%), small bowel, gastric, biliary tract, brain, and skin cancers [<xref ref-type="bibr" rid="ref46">46</xref>].</p>
<p>Frequent colonoscopic surveillance has been shown to decrease CRC incidence and CRC mortality [<xref ref-type="bibr" rid="ref47">47</xref>]. ESMO guidelines recommend colonoscopy every 1-2 years, starting between ages 20-25. Endometrial cancer screening with annual pelvic exam, pelvic ultrasound, CA-125 and endometrial sampling, starting between ages 30-35, is also recommended. ESMO also recommends testing for <italic>Helicobacter pylori</italic>, and treatment if positive, but does not recommend any screening for other Lynch-associated cancers [<xref ref-type="bibr" rid="ref4">4</xref>].</p>
</sec>
<sec id="sec2-34">
<title>Treatment</title>
<p>In the case of colon cancer in Lynch syndrome, TAC is the procedure of choice, rather than segmental colectomy, because of the superior risk reduction of metachronous CRC [<xref ref-type="bibr" rid="ref45">45</xref>]. Multiple studies have demonstrated a drastic decrease in the risk of metachronous CRC in patients undergoing TAC compared to segmental resection, despite annual endoscopic surveillance [<xref ref-type="bibr" rid="ref48">48</xref>-<xref ref-type="bibr" rid="ref50">50</xref>]. One cohort analysis showed that the risk of developing a metachronous CRC after segmental colon resection is actually quite high: 16% at 10 years, 41% at 20 years, and 62% at age 30 [<xref ref-type="bibr" rid="ref50">50</xref>]. Regardless of the choice of procedure (segmental colectomy vs. TAC), annual postoperative surveillance colonoscopy/endoscopy is recommended [<xref ref-type="bibr" rid="ref45">45</xref>]. If a female patient with Lynch syndrome is over the age of 40, finished with child-bearing, and/or undergoing colectomy, a prophylactic hysterectomy and salpingo-oophorectomy should be offered, according to the guidelines of the American Society of Colon and Rectal Surgeons [<xref ref-type="bibr" rid="ref45">45</xref>]. This recommendation is based on a study comparing women with Lynch syndrome who underwent prophylactic hysterectomy and salpingo-oophorectomy and those who did not. None of the women in the prophylactic surgery group developed endometrial or ovarian cancer, while 33% of those who did not undergo surgery developed endometrial cancer and 5% developed ovarian cancer [<xref ref-type="bibr" rid="ref51">51</xref>].</p>
<p>In the case of rectal cancer in Lynch syndrome, treatment should be the same as for sporadic rectal cancer [<xref ref-type="bibr" rid="ref45">45</xref>]. The risk of metachronous colon cancer after rectal cancer treatment is fairly high in Lynch syndrome, with one study reporting a rate of 15% at six years and another study reporting 27% after nine years [<xref ref-type="bibr" rid="ref52">52</xref>,<xref ref-type="bibr" rid="ref53">53</xref>]. Given the high risk of going on to develop metachronous colon cancer, it is reasonable to discuss a simultaneous prophylactic colectomy with the patient [<xref ref-type="bibr" rid="ref45">45</xref>].</p>
<p>In addition to surgical treatment of Lynch syndrome, medical risk reduction of CRC can be achieved with aspirin. A randomized control trial demonstrated a 60% decrease in CRC incidence and other Lynch-associated cancers when patients took aspirin 600 mg daily for at least two years [<xref ref-type="bibr" rid="ref54">54</xref>].</p>
</sec>
</sec>
<sec id="sec1-10">
<title>Familial CRC X syndrome</title>
<p>This syndrome is represented by the 40% of families who meet Amsterdam I criteria, but have no identifiable MMR mutation [<xref ref-type="bibr" rid="ref55">55</xref>]. These patients have an increased risk of CRC when compared to the general public, with a standardized incidence ratio of 2.3, which is about one third of the standardized incidence ratio of people with Lynch syndrome [<xref ref-type="bibr" rid="ref55">55</xref>]. Patients with familial CRC X syndrome do not show an increased incidence of the other Lynch-associated cancers [<xref ref-type="bibr" rid="ref55">55</xref>]. Recommended surveillance is colonoscopy every 3-5 years, starting 5-10 years earlier than the age when the youngest family member was diagnosed with CRC [<xref ref-type="bibr" rid="ref55">55</xref>]. CRC in patients with familial CRC X syndrome is treated identically to sporadic CRC.</p>
</sec>
<sec id="sec1-11">
<title>Concluding remarks</title>
<p>Although each of the above syndromes is quite rare, it is important for clinicians to know the characteristics of each syndrome and to understand the differences in cancer risks between the different conditions. This information is very important when treatment and surveillance plans are formulated for each individual patient.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgment</title>
<p>The authors would like to thank Mary Kwatkosky-Lawlor for her assistance with the review and submission process</p>
</ack>
<fn-group>
<fn fn-type="COI-statement">
<p>Conflict of Interest: None</p>
</fn>
</fn-group>
<bio id="d35e45">
<p>Oregon Health &amp; Science University, Portland, OR, USA</p>
</bio>
<ref-list>
<title>References</title>
<ref id="ref1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lichtenstein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Holm</surname>
<given-names>NV</given-names>
</name>
<name>
<surname>Verkasalo</surname>
<given-names>PK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland</article-title>
<source/>N Engl J Med
          <year>2000</year>
<volume>343</volume>
<fpage>78</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">10891514</pub-id>
</element-citation>
</ref>
<ref id="ref2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH</article-title>
<source/>Gastroenterology
          <year>2009</year>
<volume>137</volume>
<fpage>489</fpage>
<lpage>494</lpage>
<comment>494-e1</comment>
<pub-id pub-id-type="pmid">19394335</pub-id>
</element-citation>
</ref>
<ref id="ref3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galiatsatos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Foulkes</surname>
<given-names>WD</given-names>
</name>
</person-group>
<article-title>Familial adenomatous polyposis</article-title>
<source/>Am J Gastroenterol
          <year>2006</year>
<volume>101</volume>
<fpage>385</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="pmid">16454848</pub-id>
</element-citation>
</ref>
<ref id="ref4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balmaña</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Balaguer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cervantes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>D</given-names>
</name>
<collab>ESMO Guidelines Working Group</collab>
</person-group>
<article-title>Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines</article-title>
<source/>Ann Oncol
          <year>2013</year>
<volume>24</volume>
<issue>Suppl 6</issue>
<fpage>vi73</fpage>
<lpage>vi80</lpage>
<pub-id pub-id-type="pmid">23813931</pub-id>
</element-citation>
</ref>
<ref id="ref5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Björk</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Akerbrant</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Iselius</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Alm</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hultcrantz</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Epidemiology of familial adenomatous polyposis in Sweden: changes over time and differences in phenotype between males and females</article-title>
<source/>Scand J Gastroenterol
          <year>1999</year>
<volume>34</volume>
<fpage>1230</fpage>
<lpage>1235</lpage>
<pub-id pub-id-type="pmid">10636071</pub-id>
</element-citation>
</ref>
<ref id="ref6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasen</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Möslein</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Guidelines for the clinical management of familial adenomatous polyposis (FAP)</article-title>
<source/>Gut
          <year>2008</year>
<volume>57</volume>
<fpage>704</fpage>
<lpage>713</lpage>
<pub-id pub-id-type="pmid">18194984</pub-id>
</element-citation>
</ref>
<ref id="ref7">
<label>7</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Apostolides</surname>
<given-names>G</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Cameron</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Hereditary polyposis syndromes</article-title>
<source/>Current surgical therapy, CA
          <year>y2014</year>
<publisher-loc>Saunders: Philadelphia</publisher-loc>
<publisher-name>Elsevier</publisher-name>
<fpage>205</fpage>
<lpage>212</lpage>
</element-citation>
</ref>
<ref id="ref8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grover</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kastrinos</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Steyerberg</surname>
<given-names>EW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prevalence and phenotypes of <italic>APC</italic> and <italic>MUTYH</italic> mutations in patients with multiple colorectal adenomas</article-title>
<source/>JAMA
          <year>2012</year>
<volume>308</volume>
<fpage>485</fpage>
<lpage>492</lpage>
<pub-id pub-id-type="pmid">22851115</pub-id>
</element-citation>
</ref>
<ref id="ref9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spigelman</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Talbot</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Domizio</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>RK</given-names>
</name>
</person-group>
<article-title>Upper gastrointestinal cancer in patients with familial adenomatous polyposis</article-title>
<source/>Lancet
          <year>1989</year>
<volume>2</volume>
<fpage>783</fpage>
<lpage>785</lpage>
<pub-id pub-id-type="pmid">2571019</pub-id>
</element-citation>
</ref>
<ref id="ref10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brosens</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Keller</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Offerhaus</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Goggins</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giardiello</surname>
<given-names>FM</given-names>
</name>
</person-group>
<article-title>Prevention and management of duodenal polyps in familial adenomatous polyposis</article-title>
<source/>Gut
          <year>2005</year>
<volume>54</volume>
<fpage>1034</fpage>
<lpage>1043</lpage>
<pub-id pub-id-type="pmid">15951555</pub-id>
</element-citation>
</ref>
<ref id="ref11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Latchford</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Sturt</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>RK</given-names>
</name>
</person-group>
<article-title>A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis</article-title>
<source/>Br J Surg
          <year>2006</year>
<volume>93</volume>
<fpage>1258</fpage>
<lpage>1264</lpage>
<pub-id pub-id-type="pmid">16952208</pub-id>
</element-citation>
</ref>
<ref id="ref12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Cosse</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Bülow</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rectal cancer risk in patients treated for familial adenomatous polyposis. The Leeds Castle Polyposis Group</article-title>
<source/>Br J Surg
          <year>1992</year>
<volume>79</volume>
<fpage>1372</fpage>
<lpage>1375</lpage>
<pub-id pub-id-type="pmid">1336702</pub-id>
</element-citation>
</ref>
<ref id="ref13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Church</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Xhaja</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Warrier</surname>
<given-names>SK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Desmoid tumors do not prevent proctectomy following abdominal colectomy and ileorectal anastomosis in patients with familial adenomatous polyposis</article-title>
<source/>Dis Colon Rectum
          <year>2014</year>
<volume>57</volume>
<fpage>343</fpage>
<lpage>347</lpage>
<pub-id pub-id-type="pmid">24509457</pub-id>
</element-citation>
</ref>
<ref id="ref14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Remzi</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Bast</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mucosectomy vs. stapled ileal pouch-anal anastomosis in patients with familial adenomatous polyposis: functional outcome and neoplasia control</article-title>
<source/>Dis Colon Rectum
          <year>2001</year>
<volume>44</volume>
<fpage>1590</fpage>
<lpage>1596</lpage>
<pub-id pub-id-type="pmid">11711729</pub-id>
</element-citation>
</ref>
<ref id="ref15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Castro</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>van Eijck</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Rutten</surname>
<given-names>JP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pancreas-preserving total duodenectomy versus standard pancreatoduodenectomy for patients with familial adenomatous polyposis and polyps in the duodenum</article-title>
<source/>Br J Surg
          <year>2008</year>
<volume>95</volume>
<fpage>1380</fpage>
<lpage>1386</lpage>
<pub-id pub-id-type="pmid">18844249</pub-id>
</element-citation>
</ref>
<ref id="ref16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sampson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Dolwani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of <italic>MYH</italic></article-title>
<source/>Lancet
          <year>2003</year>
<volume>362</volume>
<fpage>39</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">12853198</pub-id>
</element-citation>
</ref>
<ref id="ref17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Achatz</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Brugières</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cancer screening recommendations and clinical management of inherited gastrointestinal cancer syndromes in childhood</article-title>
<source/>Clin Cancer Res
          <year>2017</year>
<volume>23</volume>
<fpage>e107</fpage>
<lpage>e114</lpage>
<pub-id pub-id-type="pmid">28674119</pub-id>
</element-citation>
</ref>
<ref id="ref18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kastrinos</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Steyerberg</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Mercado</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The PREMM(1,2,6) model predicts risk of <italic>MLH1 MSH2</italic> and <italic>MSH6</italic> germline mutations based on cancer history</article-title>
<source/>Gastroenterology
          <year>2011</year>
<volume>140</volume>
<fpage>73</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">20727894</pub-id>
</element-citation>
</ref>
<ref id="ref19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Win</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Hopper</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Association between monoallelic <italic>MUTYH</italic> mutation and colorectal cancer risk: a meta-regression analysis</article-title>
<source/>Fam Cancer
          <year>2011</year>
<volume>10</volume>
<fpage>1</fpage>
<lpage>9</lpage>
</element-citation>
</ref>
<ref id="ref20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hezel</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Bardeesy</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>LKB1; linking cell structure and tumor suppression</article-title>
<source/>Oncogene
          <year>2008</year>
<volume>27</volume>
<fpage>6908</fpage>
<lpage>6919</lpage>
<pub-id pub-id-type="pmid">19029933</pub-id>
</element-citation>
</ref>
<ref id="ref21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volikos</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Aittomäki</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>LKB1</italic> exonic and whole gene deletions are a common cause of Peutz-Jeghers syndrome</article-title>
<source/>J Med Genet
          <year>2006</year>
<volume>43</volume>
<fpage>e18</fpage>
<pub-id pub-id-type="pmid">16648371</pub-id>
</element-citation>
</ref>
<ref id="ref22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aretz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stienen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Uhlhaas</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High proportion of large genomic <italic>STK11</italic> deletions in Peutz-Jeghers syndrome</article-title>
<source/>Hum Mutat
          <year>2005</year>
<volume>26</volume>
<fpage>513</fpage>
<lpage>519</lpage>
<pub-id pub-id-type="pmid">16287113</pub-id>
</element-citation>
</ref>
<ref id="ref23">
<label>23</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Aaltonen</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Jarvinen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gruber</surname>
<given-names>SB</given-names>
</name>
<etal></etal>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Hamilton</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Aaltonen</surname>
<given-names>LA</given-names>
</name>
</person-group>
<article-title>Peutz-Jeghers syndrome</article-title>
<source/>World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Digestive System
          <year>2000</year>
<publisher-loc>Lyon</publisher-loc>
<publisher-name>IARC Press</publisher-name>
<fpage>74</fpage>
<lpage>77</lpage>
</element-citation>
</ref>
<ref id="ref24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Lier</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Westerman</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome</article-title>
<source/>Gut
          <year>2011</year>
<volume>60</volume>
<fpage>141</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="pmid">21205875</pub-id>
</element-citation>
</ref>
<ref id="ref25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howe</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Sayed</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>AF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The prevalence of <italic>MADH4</italic> and <italic>BMPR1A</italic> mutations in juvenile polyposis and absence of <italic>BMPR2 BMPR1B</italic> and <italic>ACVR1</italic> mutations</article-title>
<source/>J Med Genet
          <year>2004</year>
<volume>41</volume>
<fpage>484</fpage>
<lpage>491</lpage>
<pub-id pub-id-type="pmid">15235019</pub-id>
</element-citation>
</ref>
<ref id="ref26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jasperson</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Tuohy</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Neklason</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Burt</surname>
<given-names>RW</given-names>
</name>
</person-group>
<article-title>Hereditary and familial colon cancer</article-title>
<source/>Gastroenterology
          <year>2010</year>
<volume>138</volume>
<fpage>2044</fpage>
<lpage>2058</lpage>
<pub-id pub-id-type="pmid">20420945</pub-id>
</element-citation>
</ref>
<ref id="ref27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brosens</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>van Hattem</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hylind</surname>
<given-names>LM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Risk of colorectal cancer in juvenile polyposis</article-title>
<source/>Gut
          <year>2007</year>
<volume>56</volume>
<fpage>965</fpage>
<lpage>967</lpage>
<pub-id pub-id-type="pmid">17303595</pub-id>
</element-citation>
</ref>
<ref id="ref28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Syngal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Brand</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Giardiello</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Hampel</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Burt</surname>
<given-names>RW</given-names>
</name>
<collab>American College of Gastroenterology</collab>
</person-group>
<article-title>ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes</article-title>
<source/>Am J Gastroenterol
          <year>2015</year>
<volume>110</volume>
<fpage>223</fpage>
<lpage>262</lpage>
<comment>quiz 263</comment>
<pub-id pub-id-type="pmid">25645574</pub-id>
</element-citation>
</ref>
<ref id="ref29">
<label>29</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Mester</surname>
<given-names>J</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Boardman</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title><italic>PTEN</italic> hamartoma tumor syndrome</article-title>
<source/>Intestinal polyposis syndromes
          <year>2016</year>
<publisher-loc>Springer</publisher-loc>
<publisher-name>Switzerland</publisher-name>
<fpage>87</fpage>
<lpage>100</lpage>
</element-citation>
</ref>
<ref id="ref30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways</article-title>
<source/>Hum Mol Genet
          <year>2001</year>
<volume>10</volume>
<fpage>237</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="pmid">11159942</pub-id>
</element-citation>
</ref>
<ref id="ref31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stambolic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de la Pompa</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN</article-title>
<source/>Cell
          <year>1998</year>
<volume>95</volume>
<fpage>29</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">9778245</pub-id>
</element-citation>
</ref>
<ref id="ref32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Tumor suppressor <italic>PTEN</italic> inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways</article-title>
<source/>J Cell Biol
          <year>1998</year>
<volume>143</volume>
<fpage>1375</fpage>
<lpage>1383</lpage>
<pub-id pub-id-type="pmid">9832564</pub-id>
</element-citation>
</ref>
<ref id="ref33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Mester</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Ngeow</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rybicki</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Orloff</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Eng</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Lifetime cancer risks in individuals with germline <italic>PTEN</italic> mutations</article-title>
<source/>Clin Cancer Res
          <year>2012</year>
<volume>18</volume>
<fpage>400</fpage>
<lpage>407</lpage>
<pub-id pub-id-type="pmid">22252256</pub-id>
</element-citation>
</ref>
<ref id="ref34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mester</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Tilot</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Rybicki</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Frazier</surname>
<given-names>TW</given-names>
<suffix>2nd</suffix>
</name>
<name>
<surname>Eng</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Analysis of prevalence and degree of macrocephaly in patients with germline <italic>PTEN</italic> mutations and of brain weight in <italic>PTEN</italic> knock-in murine model</article-title>
<source/>Eur J Hum Genet
          <year>2011</year>
<volume>19</volume>
<fpage>763</fpage>
<lpage>768</lpage>
<pub-id pub-id-type="pmid">21343951</pub-id>
</element-citation>
</ref>
<ref id="ref35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalady</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Jarrar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Leach</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Defining phenotypes and cancer risk in hyperplastic polyposis syndrome</article-title>
<source/>Dis Colon Rectum
          <year>2011</year>
<volume>54</volume>
<fpage>164</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="pmid">21228663</pub-id>
</element-citation>
</ref>
<ref id="ref36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boparai</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Mathus-Vliegen</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Koornstra</surname>
<given-names>JJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study</article-title>
<source/>Gut
          <year>2010</year>
<volume>59</volume>
<fpage>1094</fpage>
<lpage>1100</lpage>
<pub-id pub-id-type="pmid">19710031</pub-id>
</element-citation>
</ref>
<ref id="ref37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rex</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Ahnen</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Baron</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serrated lesions of the colorectum: review and recommendations from an expert panel</article-title>
<source/>Am J Gastroenterol
          <year>2012</year>
<volume>107</volume>
<fpage>1315</fpage>
<lpage>1329</lpage>
<pub-id pub-id-type="pmid">22710576</pub-id>
</element-citation>
</ref>
<ref id="ref38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chow</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lipton</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hyperplastic polyposis syndrome: phenotypic presentations and the role of <italic>MBD4</italic> and <italic>MYH</italic></article-title>
<source/>Gastroenterology
          <year>2006</year>
<volume>131</volume>
<fpage>30</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="pmid">16831587</pub-id>
</element-citation>
</ref>
<ref id="ref39">
<label>39</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Snover</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Burt</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Odze</surname>
<given-names>RD</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Bosman</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Hruban</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Thieses</surname>
<given-names>ND</given-names>
</name>
</person-group>
<article-title>Serrated polyps of the colon and rectum and serrated polyposis</article-title>
<source/>WHO Classification of Tumours of the Digestive System
          <year>2000</year>
<publisher-loc>Lyon</publisher-loc>
<publisher-name>IARC Press</publisher-name>
<fpage>160</fpage>
<lpage>165</lpage>
</element-citation>
</ref>
<ref id="ref40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>de la Chapelle</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Hereditary colorectal cancer</article-title>
<source/>N Engl J Med
          <year>2003</year>
<volume>348</volume>
<fpage>919</fpage>
<lpage>932</lpage>
<pub-id pub-id-type="pmid">12621137</pub-id>
</element-citation>
</ref>
<ref id="ref41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Senter</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Clendenning</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sotamaa</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The clinical phenotype of Lynch syndrome due to germ-line <italic>PMS2</italic> mutations</article-title>
<source/>Gastroenterology
          <year>2008</year>
<volume>135</volume>
<fpage>419</fpage>
<lpage>428</lpage>
<pub-id pub-id-type="pmid">18602922</pub-id>
</element-citation>
</ref>
<ref id="ref42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasen</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mecklin</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>HT</given-names>
</name>
</person-group>
<article-title>New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC</article-title>
<source/>Gastroenterology
          <year>1999</year>
<volume>116</volume>
<fpage>1453</fpage>
<lpage>1456</lpage>
<pub-id pub-id-type="pmid">10348829</pub-id>
</element-citation>
</ref>
<ref id="ref43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Umar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boland</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Terdiman</surname>
<given-names>JP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability</article-title>
<source/>J Natl Cancer Inst
          <year>2004</year>
<volume>96</volume>
<fpage>261</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="pmid">14970275</pub-id>
</element-citation>
</ref>
<ref id="ref44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hampel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Frankel</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)</article-title>
<source/>N Engl J Med
          <year>2005</year>
<volume>352</volume>
<fpage>1851</fpage>
<lpage>1860</lpage>
<pub-id pub-id-type="pmid">15872200</pub-id>
</element-citation>
</ref>
<ref id="ref45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herzig</surname>
<given-names>DO</given-names>
</name>
<name>
<surname>Buie</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Weiser</surname>
<given-names>MR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical practice guidelines for the surgical treatment of patients with Lynch syndrome</article-title>
<source/>Dis Colon Rectum
          <year>2017</year>
<volume>60</volume>
<fpage>137</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="pmid">28059909</pub-id>
</element-citation>
</ref>
<ref id="ref46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Win</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Lindor</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Winship</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome</article-title>
<source/>J Natl Cancer Inst
          <year>2013</year>
<volume>105</volume>
<fpage>274</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="pmid">23385444</pub-id>
</element-citation>
</ref>
<ref id="ref47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Järvinen</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Aarnio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mustonen</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer</article-title>
<source/>Gastroenterology
          <year>2000</year>
<volume>118</volume>
<fpage>829</fpage>
<lpage>834</lpage>
<pub-id pub-id-type="pmid">10784581</pub-id>
</element-citation>
</ref>
<ref id="ref48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalady</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>McGannon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Manilich</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fazio</surname>
<given-names>VW</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria</article-title>
<source/>Ann Surg
          <year>2010</year>
<volume>252</volume>
<fpage>507</fpage>
<lpage>511</lpage>
<comment>discussion 511-513</comment>
<pub-id pub-id-type="pmid">20739851</pub-id>
</element-citation>
</ref>
<ref id="ref49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Natarajan</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Silva-Lopez</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>HT</given-names>
</name>
</person-group>
<article-title>Comparison of extended colectomy and limited resection in patients with Lynch syndrome</article-title>
<source/>Dis Colon Rectum
          <year>2010</year>
<volume>53</volume>
<fpage>77</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">20010355</pub-id>
</element-citation>
</ref>
<ref id="ref50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parry</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Win</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Parry</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery</article-title>
<source/>Gut
          <year>2011</year>
<volume>60</volume>
<fpage>950</fpage>
<lpage>957</lpage>
<pub-id pub-id-type="pmid">21193451</pub-id>
</element-citation>
</ref>
<ref id="ref51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmeler</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>LM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome</article-title>
<source/>N Engl J Med
          <year>2006</year>
<volume>354</volume>
<fpage>261</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="pmid">16421367</pub-id>
</element-citation>
</ref>
<ref id="ref52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalady</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Lipman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McGannon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer</article-title>
<source/>Ann Surg
          <year>2012</year>
<volume>255</volume>
<fpage>1121</fpage>
<lpage>1125</lpage>
<pub-id pub-id-type="pmid">22549751</pub-id>
</element-citation>
</ref>
<ref id="ref53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Win</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Parry</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Parry</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers</article-title>
<source/>Ann Surg Oncol
          <year>2013</year>
<volume>20</volume>
<fpage>1829</fpage>
<lpage>1836</lpage>
<pub-id pub-id-type="pmid">23358792</pub-id>
</element-citation>
</ref>
<ref id="ref54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gerdes</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Macrae</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial</article-title>
<source/>Lancet
          <year>2011</year>
<volume>378</volume>
<fpage>2081</fpage>
<lpage>2087</lpage>
<pub-id pub-id-type="pmid">22036019</pub-id>
</element-citation>
</ref>
<ref id="ref55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindor</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Rabe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>GM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X</article-title>
<source/>JAMA
          <year>2005</year>
<volume>293</volume>
<fpage>1979</fpage>
<lpage>1985</lpage>
<pub-id pub-id-type="pmid">15855431</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>